Boceprevir and treatment of chronic hepatitis C.

Abstract

The addition of boceprevir to peginterferon and ribavirin has improved sustained response rates markedly. Boceprevir is effective in treatment naïve, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavirin dose reduction is an effective strategy. This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. Further follow-up in these cohorts will be required.

• Authors: Paul Y Kwo
• Journal: Clinics in liver disease (Clin Liver Dis) Vol. 17 Issue 1 Pg. 63-72 (Feb 2013) ISSN: 1557-8224 [Electronic] United States
• PMID: 23177283 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2013 Elsevier Inc. All rights reserved.

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Serine Proteinase Inhibitors
• Polyethylene Glycols
• Ribavirin
• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
• Proline
• peginterferon alfa-2b

Topics

• Anemia (chemically induced)
• Antiviral Agents (therapeutic use)
• Coinfection (drug therapy)
• Drug Therapy, Combination
• HIV Infections (drug therapy)
• Hepacivirus (enzymology, genetics)
• Hepatitis C, Chronic (drug therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Liver Transplantation
• Polyethylene Glycols (therapeutic use)
• Proline (adverse effects, analogs & derivatives, economics, therapeutic use)
• Recombinant Proteins (therapeutic use)
• Ribavirin (therapeutic use)
• Serine Proteinase Inhibitors (adverse effects, economics, therapeutic use)